読み込み中
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
終値時点
$6.25
−$0.16 · -2.50%
時間外
$6.25
$0.00 · 0.00%
10月9日 16:00 ET
日中の時刻はETです。市場データは遅延する場合があります。
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
日中レンジ
現在 $6.25
52週レンジ
現在 $6.25
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
73
割安
センチメント
56
まちまち
リスク
67
高リスク
モメンタム
21
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
日中レンジ
現在 $6.25
52週レンジ
現在 $6.25
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$27.83
上昇余地（345.28%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI935.66万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM254.18万0.00%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF160.21万0.00%954億 USD0.05%$235+0.80%
Fidelity Enhanced Small Cap ETFFESM97.24万0.01%64.1億 USD0.28%$45.46+0.46%
Vanguard Russell 2000 ETFVTWO92.37万0.01%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO91.97万0.01%139.72億 USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA72.77万0.00%217.28億 USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT37万0.00%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
